Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:activities |
neutralizes virus
|
| gptkbp:can_be_used_with |
gptkb:tixagevimab
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:effective_date |
not approved
|
| gptkbp:first_described_by |
gptkb:2021
|
| https://www.w3.org/2000/01/rdf-schema#label |
cilgavimab
|
| gptkbp:is_used_for |
gptkb:drug
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:related_to |
gptkb:tixagevimab
|
| gptkbp:targets |
gptkb:SARS-Co_V-2
|
| gptkbp:bfsParent |
gptkb:Evusheld
|
| gptkbp:bfsLayer |
5
|